Supplier Related Products Identification Questions And Answer Chemical Properties Hazard Information Safety Data
WebSite >  CAS DataBase List  > 9005-27-0

9005-27-0

Supplier Related Products Identification Questions And Answer Chemical Properties Hazard Information Safety Data

Product Image

Identification

Name
Hydroxyethyl starch
CAS
9005-27-0
Synonyms
2-HYDROXYETHYL STARCH
HYDROXYETHYL STARCH
2-hydroxyethylstarchether
essex1360
essexgum1360
ethylexgum2020
hes
hespander
hespanderinjection
hydroxyathylstarke
o-(2-hydroxyethyl)starch
o-(hydroxyethyl)starch
penford260
penford280
penford290
penfordp208
plasmasteril
starchhydroxyethylether
tapiocastarchhydroxyethylether
Hydroxyethyl Starch 200/0.5
EINECS(EC#)
618-410-9
Molecular Formula
(C6H10O5)m(C2H5O)n
MDL Number
MFCD00131356

Questions And Answer

Clinical Uses
Hydroxyethyl starch is often used as a plasma substitute for therapy of hypo- volemia after trauma, burns, infections or during surgery.It is also widely used for hemodilution treatment of cerebral ischemia and of retinal, otogenic or peripheral perfusion disturbances.In treatment of cerebral ischemia, a hypervolemic therapy protocol has been shown to be more effective than an isovolemic infusion. Another indication is the hyperdynamic treatment of vasospasm in subarachnoid hemorrhage.Some of these indications require relatively high dosages to ensure efficacy of therapy.However, during continuous treatment with large volumes of HES, disturbances of coagulation and hemor- rhagic complications are not uncommon. Trumble et al. reported bleeding complications during hetastarch therapy of vasospasm in subarachnoid hemorrhage patients and recommended the use of plasma protein fraction instead.Van den Brink observed coagulopathy under therapy with highly sub- stituted medium molecular weight HES.These disturbances of the coagulation sys-tem were found to be due to an acquired von Willebrand syndrome.
lnstructions for Use
Suspend in saline(0.9%) or 5% dextrose solution for use. Administer slowly in 5-mL/kg increments to small animals,then reassess and increase the dose to rates listed in the dosing section.Hydroxyethyl starch solutions are used in critical care situations and infused via CRI.
Adverse Reactions and Side Effects
Most of the serious adverse effects reported, such as kidney injury and coagula- tion abnormalitics,have been observed in human studies and have not been docu- mented with clinical use in veterinary medicine.The use in people has become controversial and caution is advised when using these products in animals,with attention to the most commonly reported problems in people.Hetastarch may cause allergic reactions and hyperosmotic kidney injury.Hydroxyethyl starch solu- tions may affect platelet function and produce coagulation abnormalitics at clini- cally relevant doses for up to 24 hours.The high-molecular-weight hetastarch may alter coagulation and alter viscoelastic measurements and fibrinolysis.Do not use in patients with bleeding problems or preexisting coagulopathies. High-molecular- weight products (10% solutions) have molecular weight more than 200 kDa (kilodaltons)and are associated with higher risk of kidney injury.Tetrastarch solu- tions also may have less tendency to cause coagulopathics than hetastarch.There- fore the current recommendation is to use tetrastarch solutions of 6% and reduced molecular weight(130 kDa).

Chemical Properties

storage temp. 
-20°C
solubility 
Freely soluble in water and in dimethyl sulfoxide, practically insoluble in anhydrous ethanol. Hydroxyethyl starches are hygroscopic until they reach a water content of about 12 per cent to 15 per cent.
form 
neat
CAS DataBase Reference
9005-27-0(CAS DataBase Reference)
EPA Substance Registry System
9005-27-0(EPA Substance)

Hazard Information

Chemical Properties
DS 0.7;
Uses
blood volume expander
Brand name
Pentaspan (DuPont Merck).
Biochem/physiol Actions
Analysis of cDNA clones indicates that ribosome binding protein 1 may exist in different forms due to removal of tandem repeats, or partial intraexonic splicing of RRBP1. The form presented here is lacking the canine p180 ribosome-binding domain, NQGKKAEGAQ, which is tandemly repeated close to the N-terminus in other forms that haven′t been fully characterized. RRBP1 has been excluded as a candidate gene in the cause of Alagille syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq]

Safety Data

WGK Germany 
2

RTECS 
WI0410000

SupplierMore